Glenmark Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals submitted a Regulation 31(4) disclosure to NSE and BSE, signed by Chairman & Managing Director Glenn Saldanha. Under this SEBI regulation, promoters and persons acting in concert must annually declare that they have not created any encumbrance (pledge, lien, or similar charge) on their shares during the financial year. The filing is a routine compliance requirement with no transaction data or share movement involved. The document text appears truncated, but the standard declaration for this regulation is a negative confirmation from promoters.
This is a standard annual compliance filing and is neutral for shareholders — it confirms promoters have not pledged or encumbered their holdings, which is generally seen as a positive sign of stability and no forced-selling risk.